Menu

Press Release Details

Bruker Announces Two 1.2 GHz NMR Systems Orders from the UK

March 17, 2023

Universities of Warwick and Birmingham to receive 1.2 GHz NMRs for Enabling Life-Science and Green-Tech Research throughout the United Kingdom

Bruker announces that the United Kingdom is expanding its fundamental research infrastructure with recent orders for two 1.2 GHz Avance™ nuclear magnetic resonance (NMR) spectrometers for the University of Warwick and the University of Birmingham. Each institution already has a Bruker 1.0 GHz NMR spectrometer and will advance their capabilities further for research into the materials properties for energy storage and biofuels, as well as into structures and interactions of biomolecules such as proteins, nucleic acids, carbohydrates, lipids, and metabolites. System installations are expected in 2025, and scientists from across the UK will have access, while students can gain experience at the forefront of research.

1.2 GHz Avance™ nuclear magnetic resonance (NMR) spectrometer (Photo: Business Wire)

1.2 GHz Avance™ nuclear magnetic resonance (NMR) spectrometer (Photo: Business Wire)

The University of Warwick 1.2 GHz NMR will advance research in improved plant biofuels, batteries, and solar cells by studying molecular structures and dynamics of advanced materials. The scientific insights gained help improve efficiency and durability of renewable energy technologies, and to develop novel materials.

Professor Steven Brown from the University of Warwick Solid-State NMR Group commented: “The linking of the new 1.2 GHz spectrometer at the University of Warwick to the 850 MHz and 1 GHz systems of the UK High-Field Solid-State NMR Facility will enable UK scientists to push forward frontiers in diverse fields from batteries and catalysts to pharmaceuticals and plant biomass.”

The University of Birmingham will utilize the increased sensitivity and resolution of 1.2 GHz NMR to advance research in functional and structural biology, and drug discovery. Researchers will study the structure, function, interactions and pathways of proteins and other biomolecules. As an example, they will study the structure of enzymes involved in antibiotic resistance, which could help in development of new antibiotics.

Teresa Carlomagno, Professor and Academic Lead of HWB-NMR University of Birmingham stated: “NMR plays a unique and key role in the understanding of molecular mechanisms in health and disease contexts. This is in particular because of its ability to deal with dynamics and disorder, which are often responsible for the regulation of these mechanisms. We are excited to add the 1.2 GHz NMR from Bruker to our research infrastructure and push our biomolecular research beyond current boundaries.”

Dr. Falko Busse, President of the Bruker BioSpin Group, commented: "I am pleased to announce two orders for 1.2 GHz NMRs from the Universities of Warwick and Birmingham. Not only does GHz-class NMR advance life science research, but GHz-class NMR also advances research in batteries, biofuels, and renewable energy. Bruker supports the UK science community and looks forward to many groundbreaking discoveries.”

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Investor Contact:
Justin Ward
Sr. Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com

Source: Bruker Corporation